Bailly C, Dassonneville L, Carrasco C, Lucas D, Kumar A, Boykin D W, Wilson W D
INSERM U-524, Centre Oscar Lambert, Lille, France.
Anticancer Drug Des. 1999 Feb;14(1):47-60.
Four diphenylfuran derivatives possessing different dicationic terminal side chains were used to investigate sequence-specific binding to DNA and poisoning of human topoisomerase II. Footprinting experiments with a range of DNA substrates attest that all four drugs bind selectively to AT-rich sequences in DNA. However, the quantitative analysis of the footprinting profiles reveals significant differences in terms of AT-selectivity according to the nature of the basic side chains. Furimidazoline (DB60) shows a reduced capacity to interact selectively with A.T tetrads compared with furamidine (DB75) and the 3-pentyl-substituted diamidine analogue DB226. DB244, for which the two amidine ends are substituted with a cyclopentyl group, exhibits the most pronounced AT specificity. It binds tightly to sites composed of at least four adjacent AT base pairs, such as 5'-TAAT, AATT and TTTT. At low concentrations (< 2 microM) DB60 is also capable of forming stable complexes with AT sites but at higher concentrations the binding becomes totally non-specific due to additional intercalation of drug molecules into GC-rich sequences. Nevertheless, DB60 is the only drug is the series which stabilizes DNA-topoisomerase II covalent complexes. This compound effectively promotes DNA cleavage by topoisomerase II whereas DB75, DB226 and DB244 have practically no effect. The topoisomerase II poisoning activity of DB60 correlates with its ability to intercalate into GC sites in DNA whereas the three other diphenylfurans essentially behave as typical AT-selective minor groove binders. The study suggests that the antimicrobial activity of the diphenylfurans, which are active against the Pneumocystis carinii pathogen (PCP), depends essentially on their capacity to recognize AT-rich DNA sequences rather than their ability to interfere with topoisomerase II. In contrast, the cytotoxicity of drugs like DB60 would be connected with the formation of intercalation complexes and the stimulation of DNA cleavage by human topoisomerase II.
使用四种具有不同双阳离子末端侧链的二苯基呋喃衍生物来研究其与DNA的序列特异性结合以及对人拓扑异构酶II的毒害作用。对一系列DNA底物进行的足迹实验证明,所有四种药物均选择性地结合到DNA中富含AT的序列上。然而,足迹图谱的定量分析表明,根据碱性侧链的性质,在AT选择性方面存在显著差异。与呋喃脒(DB75)和3-戊基取代的二脒类似物DB226相比,呋喃咪唑啉(DB60)与A.T四联体选择性相互作用的能力降低。DB244的两个脒端被环戊基取代,表现出最明显的AT特异性。它紧密结合到由至少四个相邻AT碱基对组成的位点,如5'-TAAT、AATT和TTTT。在低浓度(<2 microM)下,DB60也能够与AT位点形成稳定的复合物,但在较高浓度下,由于药物分子额外插入富含GC的序列中,结合变得完全非特异性。尽管如此,DB60是该系列中唯一能稳定DNA-拓扑异构酶II共价复合物的药物。该化合物有效地促进拓扑异构酶II对DNA的切割,而DB75、DB226和DB244实际上没有作用。DB60的拓扑异构酶II毒害活性与其插入DNA中GC位点的能力相关,而其他三种二苯基呋喃基本上表现为典型的AT选择性小沟结合剂。该研究表明,对卡氏肺孢子虫病原体(PCP)有活性的二苯基呋喃的抗菌活性主要取决于它们识别富含AT的DNA序列的能力,而不是它们干扰拓扑异构酶II的能力。相比之下,像DB60这样的药物的细胞毒性将与插入复合物的形成以及人类拓扑异构酶II对DNA切割的刺激有关。